Hers Pricing History and Trajectory: What Women Should Know Before Subscribing

What Hers Actually Is and Who Regulates It

Hers is a women-facing brand operated by Hims & Hers Health, Inc., a publicly traded telehealth company (NYSE: HIMS). It offers asynchronous and synchronous consultations across hair loss, mental health, hormonal health, and weight management. Prescriptions are filled through partner pharmacies, including 503A compounding pharmacies for products not available as FDA-approved formulations at commercially viable prices.

Regulatory Oversight

Telehealth platforms like Hers are subject to oversight from multiple agencies. The FDA regulates the drugs dispensed and the pharmacies that compound them. The Federal Trade Commission governs advertising claims under 16 CFR Part 255. State medical boards license the prescribers, and state pharmacy boards license the dispensing pharmacies. The FTC has issued guidance specifically warning consumers about unsubstantiated weight-loss claims in telehealth advertising, which directly applies to platforms marketing GLP-1 medications. See FTC guidance on health product claims.

LegitScript and Pharmacy Accreditation

LegitScript, the verification service used by Google and major payment processors, lists Hims & Hers as a "licensed" telehealth operator. LegitScript's licensed designation requires proof of valid prescriber licensure, state pharmacy compliance, and adherence to applicable drug regulations. LegitScript's certification standards are publicly documented. This designation does not guarantee clinical quality or pricing transparency, but it does confirm the platform meets a baseline legal operating standard.

Hers Pricing History: A Category-by-Category Timeline

Hers does not publish an official pricing changelog, so the trajectory below is reconstructed from archived web pages, SEC filings from Hims & Hers Health, and consumer forum records. Prices are approximate and vary by state, pharmacy partner, and promotional code.

Hair Loss (2018 to 2025)

At launch, Hers positioned minoxidil topical solution as its flagship product. A monthly supply started at roughly $28, $36 for topical minoxidil 2%, consistent with generic market pricing at the time. By 2022, Hers had introduced compounded formulations combining minoxidil with tretinoin and/or finasteride-equivalent agents, priced between $44 and $75/month. The FDA has approved topical minoxidil for androgenetic alopecia in women at the 2% concentration. FDA approval records for minoxidil confirm this. Compounded multi-ingredient formulations are not FDA-approved and are dispensed under 503A pharmacy rules.

Mental Health (2020 to 2025)

Hers began offering online prescribing for SSRIs and SNRIs around 2020. A sertraline prescription started at approximately $25, $49 for the first month with a consultation included, rising to $35, $65/month thereafter depending on state. Generic sertraline costs less than $10 at retail pharmacies without a subscription, which means the Hers pricing model bundles consultation fees into the medication cost. The FDA requires a Medication Guide for sertraline, and prescribers must conduct adequate clinical evaluation before initiating antidepressants. FDA labeling requirements for sertraline are on file.

Hormonal Health / HRT (2021 to 2025)

Hers added HRT products, including estradiol and progesterone, around 2021. Pricing for a monthly HRT subscription started at approximately $49, $79/month and has climbed to $85, $125/month by early 2025, depending on the formulation. The Menopause Society (formerly NAMS) 2023 position statement confirms that hormone therapy is an appropriate first-line option for vasomotor symptoms in healthy women under 60 or within 10 years of menopause. The Menopause Society's position statement is publicly available. Hers does not currently offer pellet therapy or injectable estradiol, limiting its formulary compared to brick-and-mortar HRT clinics.

Weight Loss and GLP-1 Medications (2023 to 2025)

This is the category where pricing history is most volatile. Hers introduced compounded semaglutide in 2023 under FDA shortage-list provisions that permitted 503A pharmacies to compound semaglutide when brand-name Ozempic and Wegovy were in short supply. Starting prices were approximately $199, $249/month, framed as introductory offers.

By mid-2024, Hers raised its compounded semaglutide starting price to approximately $279, $299/month. The FDA removed semaglutide from its drug shortage list in February 2025, which triggered a compliance deadline for 503A compounding pharmacies. The FDA's drug shortage database tracks semaglutide status in real time. After removal from the shortage list, compounding pharmacies had a 90-day wind-down period. Hers publicly stated it was evaluating branded GLP-1 options for eligible patients as compounded semaglutide became unavailable.

For context, branded Wegovy (semaglutide 2.4 mg) has a list price of approximately $1,349/month in the United States. In STEP-1 (N=1,961), once-weekly semaglutide 2.4 mg produced 14.9% mean body weight reduction at 68 weeks versus 2.4% with placebo (P<0.001). The STEP-1 trial was published in the New England Journal of Medicine. The clinical evidence for semaglutide is strong; the regulatory status of compounded versions is not.

Price Trajectory: Is Hers Getting More Expensive?

The short answer is yes. Across every category Hers offers, subscription prices have risen faster than general inflation since 2020.

Comparing 2020 and 2025 Prices

Between 2020 and 2025, Hers hair subscriptions roughly doubled in price when moving from single-ingredient minoxidil to compounded formulations. Mental health subscriptions increased by approximately 30 to 50% in nominal terms. HRT subscriptions, launched later, started higher and have continued to rise. GLP-1 compounded semaglutide pricing increased by roughly 20 to 50% from its 2023 introduction to 2025.

These increases are not unique to Hers. The entire direct-to-consumer telehealth sector has raised prices as customer acquisition costs rose and post-pandemic demand normalized. Hims & Hers Health reported net revenue of $872 million for full-year 2023, up 49% from 2022, according to its SEC filings. Revenue growth at that pace typically reflects both volume and price increases.

What Drives the Price Increases

Three factors appear to be driving Hers price increases over time. First, compounding pharmacy input costs for active pharmaceutical ingredients have risen alongside global supply chain pressures. Second, Hers bundles provider consultation fees into subscription prices, and provider costs have risen as demand for telehealth clinicians increased. Third, the platform has shifted its product mix toward higher-margin compounded formulations.

The FDA requires compounding pharmacies to use pharmaceutical-grade active pharmaceutical ingredients from FDA-registered suppliers. FDA oversight of 503A compounding pharmacies is detailed in its guidance documents. This requirement adds cost legitimately but also creates a margin layer when platforms mark up compounded products above retail pharmacy prices for the same generics.

Hers Complaints: What the Record Shows

BBB Complaint Data

The Better Business Bureau lists Hims & Hers Health with a B+ rating and more than 1,000 complaints filed over a three-year period as of early 2025. The three most common complaint categories are billing and subscription cancellation issues, delayed or missing shipments, and dissatisfaction with clinical outcomes. The BBB complaint record is not a regulatory finding, but it provides a consumer-experience signal. BBB records for Hims & Hers are publicly searchable.

Cancellation and Auto-Renewal Complaints

A recurring theme in consumer complaints is difficulty canceling subscriptions before auto-renewal charges. California, New York, and several other states have automatic renewal laws requiring clear disclosure and easy cancellation. The California Automatic Renewal Law (Business & Professions Code Section 17600) mandates that cancellation must be possible through a simple online mechanism. California's consumer protection statutes are maintained by the state legislature. Hers has an online cancellation portal, but multiple consumer reviews describe multi-step processes that led to unintended charges.

FDA Warning Letters to the GLP-1 Telehealth Sector

The FDA sent warning letters to several telehealth compounding operations in late 2024 for making unsupported efficacy claims about compounded semaglutide. Hers was not listed as a named recipient in the warning letters published through early 2025. FDA warning letters are publicly searchable by company name. The absence of a named warning letter is not a clean bill of health, but it is a meaningful distinction from platforms that did receive formal FDA action.

State Medical Board Actions

No state medical board had published a formal disciplinary action against Hers-affiliated prescribers as of early 2025, based on publicly searchable state board records. Prescribers operating through telehealth platforms are individually licensed and individually subject to state board oversight. Patients can verify a prescriber's license status through the Federation of State Medical Boards' DocInfo database. FSMB's DocInfo tool is publicly available.

Is Hers Clinically Appropriate? What the Evidence Actually Shows

Hers operates across four clinical categories with very different evidence bases. The table below summarizes what primary medical literature and FDA approvals actually support for the products Hers commonly prescribes.

| Hers Product Category | FDA-Approved Option Available? | Evidence Level | Key Citation | |---|---|---|---| | Minoxidil topical 2% (hair) | Yes | RCT-supported | FDA NDA 019501 | | Sertraline (mental health) | Yes | Multiple RCTs; NICE guidelines | FDA label NDA 019839 | | Estradiol + progesterone (HRT) | Yes | WHI, NAMS 2023 position | NAMS menopause.org | | Compounded semaglutide (weight) | No (brand shortage-dependent) | Strong for branded; uncertain for compounded purity | NEJM STEP-1 |

The clinical evidence for branded semaglutide, approved estradiol formulations, generic sertraline, and topical minoxidil is well-established. The question for Hers is not whether the drug classes work. The question is whether the compounded formulations Hers has historically dispensed meet the same quality standards as FDA-approved products, and whether the consultation model is clinically adequate for the conditions being treated.

The American Society of Health-System Pharmacists has stated that compounded preparations should only be used when a commercially available product does not meet a patient's clinical needs. ASHP's position on compounding is documented in its guidelines. Hers has offered compounded semaglutide at a lower price than branded Wegovy, which may meet a financial need, but that does not satisfy the ASHP clinical-need standard once a shortage ends.

What the STEP-1 Trial Means for Hers Patients

STEP-1 (N=1,961) demonstrated that semaglutide 2.4 mg once weekly produced 14.9% mean body weight loss at 68 weeks. Published in NEJM, December 2020. That result was for pharmaceutical-grade, FDA-approved Wegovy manufactured under GMP conditions. Compounded semaglutide is not required to demonstrate bioequivalence to Wegovy. Patients paying $299/month for compounded semaglutide through Hers may not achieve identical clinical outcomes if the compounded product has variable potency.

HRT: Where Hers Has a Stronger Case

For HRT, Hers prescribes FDA-approved estradiol and progesterone products, not custom-compounded bio-identical formulations. This is a meaningful clinical distinction. The Endocrine Society's 2015 guidelines on menopausal hormone therapy state that FDA-approved hormone therapy formulations have an established safety and efficacy profile, while custom-compounded bio-identical hormones lack that evidence base. Endocrine Society clinical practice guidelines are available at endocrine.org. Hers prescribing FDA-approved HRT formulations puts it on better regulatory and clinical footing than platforms that exclusively use custom-compounded hormones.

How Hers Pricing Compares to Alternatives

Direct Competitors

Ro Body (Ro's weight-loss arm) launched compounded semaglutide at similar price points to Hers, approximately $199, $299/month in 2023 to 2024. Calibrate has shifted toward branded GLP-1s with insurance navigation, with out-of-pocket costs varying widely. Found Health prices compounded semaglutide in a similar range. None of these platforms publish audited pharmacy quality data, making price-per-milligram comparisons unreliable for assessing value.

Retail Pharmacy Comparison

Generic sertraline at a retail pharmacy with a GoodRx coupon costs approximately $4, $15/month for a 30-day supply of 50 mg tablets. A Hers mental health subscription at $35, $65/month therefore costs approximately 3 to 10 times more for the same molecule, with the premium representing the bundled telehealth consultation. Patients with existing primary care relationships may find better value through their own prescriber plus retail pharmacy for simple generic medications.

Insurance and HSA Eligibility

Hers subscription fees are generally not covered by commercial health insurance. However, the consultation fee component may be reimbursable through HSA or FSA accounts as a qualified medical expense under IRS Publication 502. IRS Publication 502 defines qualified medical expenses. Patients should request itemized receipts separating consultation fees from product costs to support HSA claims.

Practical Guidance for Prospective Hers Patients

Before You Subscribe

Check the current price on the Hers website, then calculate the annual cost. For GLP-1 medications, factor in that price may increase as compounded semaglutide availability narrows. The CDC's 2022 obesity prevalence data show that 41.9% of U.S. Adults have obesity, meaning demand for GLP-1 access will remain high and pricing pressure will persist. CDC obesity prevalence data are published in NCHS Data Brief No. 360.

Questions to Ask Before Starting

Ask Hers which specific pharmacy will fill your prescription, whether that pharmacy is NABP-accredited, and what the lot-testing or certificate-of-analysis process is for compounded medications. These are reasonable questions any patient should ask any compounding pharmacy. The FDA's guidance on what to ask a compounding pharmacy is available on its website. FDA patient guidance on compounding is publicly posted.

Cancellation Protocol

Before subscribing, read the cancellation terms in the Hers terms of service and take a screenshot. Log the exact cancellation steps. Set a calendar reminder for three days before your billing renewal date. If you encounter a cancellation barrier, the FTC's complaint portal at ReportFraud.ftc.gov accepts telehealth complaints, as does your state attorney general's consumer protection office.